clofibric acid and Cardiovascular Diseases

clofibric acid has been researched along with Cardiovascular Diseases in 110 studies

Research

Studies (110)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	6 (5.45)	18.2507
2000's	94 (85.45)	29.6817
2010's	10 (9.09)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S	1
Codario, RA	1
Harper, CR; Jacobson, TA	1
Edavalath, M; Rees, A	1
Harangi, M; László, M; Paragh, G	1
Maes, M; Staels, B; Zambon, A	1
Balmer, ML; Dufour, JF	1
Hays, R; Underberg, JA	1
Gorkin, JU; Knopp, RH; Watson, K	1
Anantharamaiah, GM; Chaddha, M; Datta, G; Garber, DW; Gupta, H; Handattu, SP; Mishra, VK; Palgunachari, MN; White, CR; Zhang, Z	1
Manzato, E; Marchiori, M; Zambon, A	1
Gandotra, P; Miller, M	1
Toth, PP	1
Pitt, B; Rosenson, RS	1
Hausenloy, DJ; Yellon, DM	2
Dominiczak, M	1
Cardenas, GA; Cardenas, V; Lavie, CJ; McCullough, PA; Milani, RV	1
Arora, R; Seth Loomba, R	1
Hughes, S	1
Ansquer, JC; Aubonnet, P; Foucher, C; Le Malicot, K	1
Darrow, B; Nair, AP	1
Mach, F; Montecucco, F	1
Arora, RR; Saha, SA	1
Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA	1
Merkel, M	1
Wierzbicki, AS	2
Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V	1
Miller, M	1
Lahoz, C; Mostaza, JM	1
Drexel, H	1
Abourbih, S; Eisenberg, MJ; Filion, KB; Genest, J; Joseph, L; Pilote, L; Poirier, P; Rinfret, S; Schiffrin, EL	1
Ginsberg, HN; Maccallum, PR	1
Reddy, HK; Sharma, RK; Singh, VN	1
Januszewicz, A	1
Haberka, M; Okopień, B; Sierant, M	1
Fiévet, C; Staels, B	1
Nakajima, K	1
Cass, A; Chalmers, J; Foote, C; Grobbee, DE; Jun, M; Lv, J; Neal, B; Nicholls, SJ; Patel, A; Perkovic, V	1
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K	1
Staels, B	1
Ruiz, J	1
Delanaye, P; Scheen, AJ	1
Braillon, A	1
Brook, RD; Rosenson, RS; Rubenfire, M	1
Elisaf, M; Kostoula, A	1
Robins, SJ	1
Jonkers, IJ; Smelt, AH; van der Laarse, A	1
Reasner, CA; Rosenson, RS	1
Khera, A; McGuire, DK	1
Hanefeld, M	1
Briel, M; Bucher, HC; Glass, TR; Leimenstoll, B; Studer, M	1
Mosca, L	1
Kashyap, ML; Meyers, CD	1
Chapman, MJ	1
Fruchart, JC; Staels, B	1
Chinetti-Gbaguidi, G; Fruchart, JC; Staels, B	2
Kon, YC	1
Laakso, M	1
Han, SH; Koh, KK; Quon, MJ	1
Gouni-Berthold, I; Krone, W	2
Cockerill, GW; Reed, SC; Thompson, MM	1
Sax, PE	1
Berneis, K; Rizzo, M	1
Balbisi, EA	1
Ilyés, I; Jancsó, Z; Simay, A; Varga, Z	1
Barter, PJ; Rye, KA	2
Allemann, S; Christ, ER; Diem, P; Egger, M; Stettler, C	1
Charlton-Menys, V; Durrington, P	1
Roberts, BH; Thompson, PD	1
Rosenson, RS	1
Schiffrin, EL; Touyz, RM	1
Bloomfield, HE; Robins, SJ	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP	1
Konstantinov, VO; Saĭfulina, IaR	1
Backes, JM; Gibson, CA; Howard, PA	1
Brown, WV	1
Taskinen, MR	1
Moulin, P	1
Fishman, I; Guttmann, H; Keidar, S; Shapira, C; Stam, T	1
Jacobson, TA; Miller, M; Schaefer, EJ	1
Márk, L; Ofner, P; Pados, G; Paragh, G; Zámolyi, K	1
Miyauchi, K	1
Benatar, JR; Stewart, RA	1
Ballantyne, CM	1
Popescu, L; Rau, O; Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H	1
Arora, RR; Bahekar, A; Kizhakepunnur, LG; Saha, SA	1
Davidson, MH	1
Peter, R; Usman, M	1
Chinetti-Gbaguidi, G; Staels, B	1
Andrulionyte, L; Kuusisto, J; Laakso, M	1
Ancelin, ML; Carrière, I; Cristol, JP; Dartigues, JF; Dupuy, AM; Gambert, P; Ritchie, K; Scali, J	1
Fazio, S	1
Brinton, EA	1
Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P	1
Brown, BG; Zhao, XQ	1
Paumelle, R; Staels, B	1
Gerich, JE	1
Doggrell, SA	1
Bruckert, E; Chapman, MJ	1
Bruckert, E; Turpin, G	1
Byrne, DJ; Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Spyropoulos, KA; Winder, AF	1
Ganotakis, ES; Jagroop, IA; Mikhailidis, DP; Papadakis, JA; Winder, AF	1
Dimmitt, SB; Watts, GF	1
Bassett, CL; Puil, L; Wright, JM	1
Dude, H; Fischer, S; Hanefeld, M; Julius, U; Rothe, G; Schmechel, H; Schulze, J; Schwanebeck, U	1

Reviews

84 review(s) available for clofibric acid and Cardiovascular Diseases

Article	Year
Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11 Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke	2016
Managing dyslipidemia in chronic kidney disease. Journal of the American College of Cardiology, 2008, Jun-24, Volume: 51, Issue:25 Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty Acids, Omega-3; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Niacin	2008
[New trends in lipidology: the increasing role of HDL-cholesterol]. Orvosi hetilap, 2008, Jul-27, Volume: 149, Issue:30 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Niacin; Nicotinic Agonists; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Phospholipids; Receptor, Cannabinoid, CB1; Receptors, Cytoplasmic and Nuclear; Risk Factors; Risk Reduction Behavior	2008
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:9 Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; PPAR alpha; Risk Assessment; Risk Factors; Treatment Outcome	2008
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. Swiss medical weekly, 2008, Jul-26, Volume: 138, Issue:29-30 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Risk Factors; Ursodeoxycholic Acid	2008
Bridging the gap in treatment options for patients with hypertriglyceridemia. The Journal of family practice, 2007, Volume: 56, Issue:12 Suppl N Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Comorbidity; Drug Monitoring; Drug Therapy, Combination; Family Practice; Fatty Acids, Omega-3; Female; Health Planning Guidelines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Life Style; Niacin; Primary Health Care; Risk Factors; Treatment Outcome; Triglycerides	2007
Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia. The Journal of family practice, 2007, Volume: 56, Issue:8 Suppl St Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Exercise; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Male; Middle Aged; Niacin; Risk Factors	2007
HDL therapy for cardiovascular diseases: the road to HDL mimetics. Current atherosclerosis reports, 2008, Volume: 10, Issue:5 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Liver; Peptide Fragments	2008
The role of triglycerides in cardiovascular risk. Current cardiology reports, 2008, Volume: 10, Issue:6 Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Life Style; Niacin; Risk Factors; Triglycerides	2008
When high is low: raising low levels of high-density lipoprotein cholesterol. Current cardiology reports, 2008, Volume: 10, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metabolic Syndrome; Niacin; Risk Factors; Thiazolidinediones	2008
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgraduate medical journal, 2008, Volume: 84, Issue:997 Topics: Antioxidants; Apolipoprotein A-I; Apoptosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biological Availability; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Niacin; Nitric Oxide; Risk Factors; Risk Reduction Behavior; Thrombosis	2008
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Reviews in cardiovascular medicine, 2008,Fall, Volume: 9, Issue:4 Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Diet; Down-Regulation; Drug Therapy, Combination; Drugs, Investigational; Dyslipidemias; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Peptides; Receptors, Prostaglandin; Risk Reduction Behavior; Treatment Outcome; Weight Loss	2008
Fibrates: where are we now? Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:1 Topics: C-Reactive Protein; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Risk Assessment; Treatment Outcome; Triglycerides	2009
Fibrates and microvascular complications in diabetes--insight from the FIELD study. Current pharmaceutical design, 2009, Volume: 15, Issue:5 Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Fenofibrate; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors	2009
Lipid management in the geriatric patient. Endocrinology and metabolism clinics of North America, 2009, Volume: 38, Issue:1 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Factors	2009
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:5 Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Mice; Peroxisome Proliferator-Activated Receptors; Risk Factors	2009
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. International journal of cardiology, 2010, May-28, Volume: 141, Issue:2 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Lipids; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention	2010
The use of lipid-lowering drug therapy in children and adolescents. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:3 Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome	2009
[Diabetic dyslipoproteinemia: beyond LDL]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicron Remnants; Clofibric Acid; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Triglycerides; Weight Loss	2009
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current opinion in cardiology, 2009, Volume: 24, Issue:4 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Mellitus; Dyslipidemias; Homocysteine; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin	2009
[HDL-cholesterol: from risk factor to therapeutic target]. Medicina clinica, 2009, Jul-11, Volume: 133, Issue:6 Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypercholesterolemia; Niacin; Risk Factors	2009
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current opinion in cardiology, 2009, Volume: 24, Issue:5 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Risk Factors; Risk Reduction Behavior; Simvastatin; United Kingdom	2009
Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:6 Topics: Anion Exchange Resins; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Risk Reduction Behavior	2009
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. The American journal of medicine, 2009, Volume: 122, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome	2009
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:9 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Obesity	2009
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vascular health and risk management, 2009, Volume: 5 Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Assessment; Risk Factors; Treatment Outcome; Triglycerides	2009
[Influence of ACE inhibitors and fibrates on endothelial function]. Kardiologia polska, 2005, Volume: 62 Suppl 2 Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Endothelium, Vascular; Humans	2005
[Pleiotropic action of ACE-I and fibrates]. Kardiologia polska, 2005, Volume: 62 Suppl 2 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Lipid Peroxidation; Oxidative Stress	2005
Combination therapy of statins and fibrates in the management of cardiovascular risk. Current opinion in lipidology, 2009, Volume: 20, Issue:6 Topics: Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Treatment Outcome	2009
Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. Current clinical pharmacology, 2010, Volume: 5, Issue:2 Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Metabolic Syndrome	2010
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (London, England), 2010, May-29, Volume: 375, Issue:9729 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome	2010
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. The American journal of medicine, 2010, Volume: 123, Issue:10 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipid Metabolism; Niacin; Phenotype; Risk Factors; Risk Reduction Behavior	2010
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Complications; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Metabolic Syndrome; Myocardial Infarction; Stroke; Treatment Outcome	2003
Hypertriglyceridemia: associated risks and effect of drug treatment. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2001, Volume: 1, Issue:6 Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Feeding Behavior; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Lipids; Risk Factors; Triglycerides	2001
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Current opinion in cardiology, 2004, Volume: 19, Issue:5 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Risk Factors	2004
Management of diabetic dyslipidemia: need for reappraisal of the goals. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005, Volume: 5, Issue:2 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents	2005
Outcome studies in type 2 diabetes. Current medical research and opinion, 2005, Volume: 21 Suppl 1 Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2005
Effect of different antilipidemic agents and diets on mortality: a systematic review. Archives of internal medicine, 2005, Apr-11, Volume: 165, Issue:7 Topics: Cardiovascular Diseases; Clofibric Acid; Diet, Fat-Restricted; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2005
Management of dyslipidemia in women in the post-hormone therapy era. Journal of general internal medicine, 2005, Volume: 20, Issue:3 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides	2005
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Current opinion in cardiology, 2005, Volume: 20, Issue:4 Topics: Amides; Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Clofibric Acid; Esters; Glycoproteins; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Sulfhydryl Compounds; Thiazolidinediones	2005
Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:2 Topics: Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2005
Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 2005, Volume: 54, Issue:8 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflammation; Insulin Resistance; Metabolic Syndrome; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Thiazolidinediones	2005
Pleiotropic effects of fibrates. Current atherosclerosis reports, 2005, Volume: 7, Issue:5 Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hypolipidemic Agents; PPAR alpha	2005
Lipids in type 2 diabetes. Seminars in vascular medicine, 2002, Volume: 2, Issue:1 Topics: Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins	2002
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:5 Topics: Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Humans; Lipoproteins; PPAR alpha; Risk Factors	2005
Hypertriglyceridemia-why, when and how should it be treated? Zeitschrift fur Kardiologie, 2005, Volume: 94, Issue:11 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Comorbidity; Evidence-Based Medicine; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Niacin; Risk Assessment; Risk Factors; Risk Reduction Behavior	2005
Therapeutic approaches to raising plasma HDL-cholesterol levels. Nature clinical practice. Cardiovascular medicine, 2004, Volume: 1, Issue:2 Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Glycoproteins; Humans; Treatment Outcome	2004
Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2005, Volume: 10 Suppl 1 Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Clofibric Acid; Humans; Inflammation; Metabolic Syndrome; PPAR alpha; PPAR gamma; Thiazolidinediones	2005
Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS care, 2006, Volume: 18, Issue:2 Topics: Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clofibric Acid; Drug Interactions; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Risk Reduction Behavior	2006
Low-density lipoprotein size and cardiovascular risk assessment. QJM : monthly journal of the Association of Physicians, 2006, Volume: 99, Issue:1 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, LDL; Particle Size; Risk Assessment; Risk Factors	2006
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Style; Niacin; Risk Factors	2006
Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation, 2006, Mar-28, Volume: 113, Issue:12 Topics: Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids	2006
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Current medical research and opinion, 2006, Volume: 22, Issue:3 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic	2006
Apolipoproteins AI and B as therapeutic targets. Journal of internal medicine, 2006, Volume: 259, Issue:5 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles	2006
Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women? Gender medicine, 2006, Volume: 3, Issue:1 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Evidence-Based Medicine; Female; Humans; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Primary Prevention; Risk Factors; Women's Health	2006
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascular pharmacology, 2006, Volume: 45, Issue:1 Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Muscle, Smooth, Vascular; PPAR alpha; PPAR gamma; Thiazolidinediones	2006
Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Current opinion in lipidology, 2006, Volume: 17, Issue:4 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Randomized Controlled Trials as Topic	2006
Dyslipidaemia, hypercoagulability and the metabolic syndrome. Current vascular pharmacology, 2006, Volume: 4, Issue:3 Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Factor VII; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Insulin Resistance; Life Style; Lipoproteins, LDL; Metabolic Syndrome; Obesity; Plasminogen Activator Inhibitor 1; Thrombophilia; Triglycerides; von Willebrand Factor	2006
[Favorable effects of decreasing lipids in patients with diabetes mellitus]. Deutsche medizinische Wochenschrift (1946), 2006, Volume: 131 Suppl 8 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Risk Factors; Treatment Outcome	2006
Fibrates after the FIELD study: Some answers, more questions. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome	2006
[Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates]. Kardiologiia, 2006, Volume: 46, Issue:11 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Metabolic Syndrome; Treatment Outcome	2006
Optimal lipid modification: the rationale for combination therapy. Vascular health and risk management, 2005, Volume: 1, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome	2005
Expert commentary: the safety of fibrates in lipid-lowering therapy. The American journal of cardiology, 2007, Mar-19, Volume: 99, Issue:6A Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Databases, Factual; Dyslipidemias; Expert Testimony; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents	2007
Hypertriglyceridemia and cardiovascular risk reduction. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Risk Reduction Behavior; Thiazolidinediones	2007
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:1 Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Myocardial Infarction; PPAR alpha; Randomized Controlled Trials as Topic	2008
[Role of fibrate in cardiovascular disease prevention]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jul-28, Volume: 65 Suppl 7 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hyperlipidemias	2007
Is it time to stop treating dyslipidaemia with fibrates? The New Zealand medical journal, 2007, Sep-07, Volume: 120, Issue:1261 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic	2007
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. Clinical cornerstone, 2007, Volume: 8 Suppl 6 Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Risk Factors	2007
The treatment of dyslipidemia--what's left in the pipeline? ChemMedChem, 2008, Volume: 3, Issue:2 Topics: Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Dyslipidemias; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors; Risk Factors; Sterol O-Acyltransferase; Treatment Outcome; Triglycerides	2008
The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. American heart journal, 2007, Volume: 154, Issue:5 Topics: Cardiovascular Diseases; Clofibric Acid; Follow-Up Studies; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	2007
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. The American heart hospital journal, 2007,Fall, Volume: 5, Issue:4 Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin	2007
Measuring biomarkers to assess the therapeutic effects of PPAR agonists? Pharmacogenomics, 2007, Volume: 8, Issue:11 Topics: Animals; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Metabolic Syndrome; Peroxisome Proliferator-Activated Receptors; Thiazolidinediones; Treatment Outcome	2007
Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Current atherosclerosis reports, 2007, Volume: 9, Issue:4 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Peroxisome Proliferator-Activated Receptors; Risk Reduction Behavior; Thiazolidinediones	2007
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clinical therapeutics, 2008, Volume: 30, Issue:2 Topics: Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Treatment Outcome	2008
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Rhabdomyolysis; Risk Assessment; Triglycerides	2008
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperlipidemias; Hypertriglyceridemia; Niacin; Risk Factors	2008
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperlipidemias; Niacin; Risk Factors; Risk Reduction Behavior	2008
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends in cardiovascular medicine, 2008, Volume: 18, Issue:3 Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PPAR alpha; Signal Transduction	2008
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. Clinical cornerstone, 2007, Volume: 8, Issue:3 Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Dyslipidemias; Humans; Risk Factors; Risk Reduction Behavior; Thiazolidinediones	2007
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis, 1996, Volume: 124 Suppl Topics: Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Risk Factors; Triglycerides	1996
Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis, 1996, Volume: 124 Suppl Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Safety; Treatment Outcome	1996
Fibrates, dyslipoproteinaemia and cardiovascular disease. Current opinion in lipidology, 1999, Volume: 10, Issue:6 Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins	1999
Analysis of serious adverse events. Lipid-lowering therapy revisited. Canadian family physician Medecin de famille canadien, 2002, Volume: 48 Topics: Cardiovascular Diseases; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Mortality; Patient Selection; Risk	2002

Trials

2 trial(s) available for clofibric acid and Cardiovascular Diseases

Article	Year
Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Current atherosclerosis reports, 2006, Volume: 8, Issue:3 Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Middle Aged; Placebos; Triglycerides	2006
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes care, 1991, Volume: 14, Issue:4 Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Education as Topic; Risk Factors; Statistics as Topic; Survival Rate	1991

Other Studies

24 other study(ies) available for clofibric acid and Cardiovascular Diseases

Article	Year
Hypertriglyceridemia and cardiovascular disease management. Journal of the American Academy of Nurse Practitioners, 2007, Volume: 19, Issue:12 Suppl 2 Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Disease Management; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Nurse Practitioners; Practice Guidelines as Topic; Primary Health Care; Risk Factors; Risk Reduction Behavior	2007
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management. Current opinion in lipidology, 2008, Volume: 19, Issue:4 Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Risk	2008
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors	2008
Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nature clinical practice. Cardiovascular medicine, 2009, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Triglycerides	2009
Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates. Current opinion in lipidology, 2009, Volume: 20, Issue:1 Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Male	2009
On the road to better dyslipidemia outcomes. The Nurse practitioner, 2009, Volume: 34, Issue:2 Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex	2009
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Current medical research and opinion, 2009, Volume: 25, Issue:6 Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans; Hypertriglyceridemia; Hypoalphalipoproteinemias; Hypolipidemic Agents; Male; Managed Care Programs; Middle Aged; Niacin; Prevalence; Retrospective Studies; Risk Factors; Triglycerides	2009
Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM : monthly journal of the Association of Physicians, 2009, Volume: 102, Issue:9 Topics: Cardiovascular Diseases; Clofibric Acid; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Factors	2009
Lipid-lowering agents and new onset diabetes mellitus. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:12 Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Patient Selection; Risk Assessment; Risk Factors	2010
Fibrates in CVD: a step towards personalised medicine. Lancet (London, England), 2010, May-29, Volume: 375, Issue:9729 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PPAR alpha	2010
[On behalf and the extent of evidence]. Revue medicale suisse, 2010, Jun-09, Volume: 6, Issue:252 Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Treatment Failure	2010
Effects of fibrates on cardiovascular outcomes. Lancet (London, England), 2010, Sep-25, Volume: 376, Issue:9746 Topics: Biomarkers; Cardiovascular Diseases; Clofibric Acid; Creatinine; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Treatment Outcome	2010
Effects of fibrates on cardiovascular outcomes. Lancet (London, England), 2010, Sep-25, Volume: 376, Issue:9746 Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Risk Assessment; Treatment Outcome	2010
Fibrates and C-reactive protein. Clinica chimica acta; international journal of clinical chemistry, 2003, Volume: 328, Issue:1-2 Topics: C-Reactive Protein; Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors	2003
High-density lipoprotein cholesterol: ready for prime time? Singapore medical journal, 2005, Volume: 46, Issue:10 Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus; Gemfibrozil; Glycoproteins; Humans; Mutation; Risk Factors	2005
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. Orvosi hetilap, 2005, Dec-25, Volume: 146, Issue:52 Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity of Patient Care; Drug Prescriptions; Dyslipidemias; Family Practice; Female; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Smoking; Surveys and Questionnaires	2005
The role of PPAR-alpha agonists in the prevention of CVD in diabetes. Current diabetes reports, 2007, Volume: 7, Issue:2 Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; PPAR alpha; Randomized Controlled Trials as Topic	2007
[Metabolically designed treatments: from biochemistry to the vessel lining]. La Revue de medecine interne, 2007, Volume: 28 Suppl 1 Topics: Biguanides; Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Thiazolidinediones	2007
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones	2007
Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clinical drug investigation, 2007, Volume: 27, Issue:9 Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Surveys and Questionnaires; Treatment Outcome	2007
Fibrate therapy: safety considerations. Current opinion in lipidology, 2007, Volume: 18, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors	2007
Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. Climacteric : the journal of the International Menopause Society, 2008, Volume: 11, Issue:1 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Risk Factors; Surveys and Questionnaires; Triglycerides	2008
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. International angiology : a journal of the International Union of Angiology, 1998, Volume: 17, Issue:4 Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipoproteins; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Risk Factors	1998
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. International journal of cardiology, 1999, Jun-01, Volume: 69, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibric Acids; Fluvastatin; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged; Pilot Projects; Treatment Outcome	1999